Analyst Soumit Roy of JonesTrading maintained a Buy rating on Evaxion Biotech, retaining the price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors that highlight Evaxion Biotech’s promising future prospects. One of the main reasons is the potential business development activities surrounding Evaxion’s EVX-01 and other pipeline assets. The anticipation of strategic partnerships or out-licensing agreements for EVX-01, a personalized cancer vaccine, is a significant factor. The vaccine’s unique approach, using AI-Immunology to identify neoantigens based on individual tumor profiles, adds to its appeal.
Additionally, there are two key catalysts expected in 2026 that could drive the company’s growth. The first is Merck’s decision on whether to in-license the infectious disease vaccine EVX-B2, which could result in substantial milestone payments for Evaxion. The second is the upcoming three-year follow-up data for EVX-01 in advanced melanoma, which has already shown promising clinical responses. These developments, along with the planned clinical development of EVX-04 in acute myeloid leukemia, underscore the company’s expanding pipeline and potential for future success.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.